News

PiR’s Diversity Report Findings

“Females are likely to be the highest earner in their household”; this is one of the findings from PiR’s recent Diversity Survey for senior executives in the life science industry. PiR commissioned the Survey to identify if there is any disparity of reward focused around gender within the life science sector.More »09 July 2018

Abingworth Raises $315m for ABV VII

Abingworth, the international investment group dedicated to life sciences, today announced the final closing of its latest fund, Abingworth Bioventures VII (ABV VII) at $315 million.More »09 July 2018

Acquisition strengthens BioIVT’s transporter sciences capabilities and enables it to partner with customers on new drug applications and mechanistic studies related to transporters.More »09 July 2018

AMSBIO Launch New Screening Company

ScreenIn3D (Glasgow, UK) is a new joint venture company set up by AMSBIO and the University of Strathclyde exploiting the latest advances in microfluidics and 3D culture to develop a novel microfluidic screening platform.More »05 July 2018

Eight life science start-ups will pitch head-to-head on 11th July to win access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham
More »04 July 2018

Concept Life Sciences Appoints John Vu as West Coast Business Development Director

Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed John Vu as Business Development Director for the West Coast, to further expand the group’s presence in and support for the US market.More »04 July 2018

Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division.More »03 July 2018

Arecor Successfully Defends a Key European Polysaccharide Vaccine Patent in its Opposition Proceedings

Cambridge, UK., 3rd July 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals and vaccines via its innovative formulation technology, continues to add to its strong patent portfolio protecting the Company’s proprietary Arestat™ technology and product assets. Arecor is pleased to announce the successful outcome to its opposition proceedings at the European Patent Office in relation to a key patent of the Company’s broad portfolio.More »03 July 2018

EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to enable scalable and high-fidelity gene synthesis, announced today that it had been awarded substantial funding to support the development of a novel enzymatic approach to DNA synthesis. Innovate UK, the UK’s innovation agency, will co-fund the £1.3 million project, which will be undertaken in collaboration with Durham University.More »03 July 2018

IONTAS Celebrates 5 Years of Antibody Discovery

IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, is celebrating its fifth anniversary. To mark the occasion, the Company held an anniversary party at King’s College, Cambridge, on 30th June 2018, with drinks, dinner and live music.More »02 July 2018